Damora Therapeutics, Inc. (DMRA) Stock
4 of the hedge funds AlphaScala tracks reported DMRA in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Viking Global Investors's at $60.11M. Company insiders reported 1 open-market buy and 0 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
Which hedge funds own DMRA?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Viking Global Investors Andreas Halvorsen | 2.31M | $60.11M | n/a |
| Blackstone | 1.00M | $26.09M | +99% |
| Citadel Ken Griffin | 166K | $4.33M | NEW |
| Point72 Steve Cohen | 49K | $1.27M | -96% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Damora Therapeutics, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 25, 26 | Jarrett Jennifer | Director, President and CEO | BUY | 12.5K | $253K |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →DMRA price chart
Powered by TradingViewWhat does Damora Therapeutics, Inc. do?
Damora Therapeutics, Inc. is a clinical-stage biotechnology company developing small molecule therapeutics targeting fibrosis, cancer, inflammation, and related diseases. Its lead candidates include GB3226, a preclinical dual inhibitor of ENL-YEATS and FLT3 aimed at blood cancer indications such as acute myeloid leukemia and myeloproliferative neoplasms, and GB1211, an oral galectin-3 inhibitor for various oncology and liver disease applications. The company focuses on advancing innovative treatments that address unmet needs in hematologic malignancies and fibrotic conditions through precise molecular targeting. Damora Therapeutics, Inc. operates in the biopharmaceutical sector, contributing to the pipeline of novel therapies for severe diseases by leveraging expertise in inhibitor design and preclinical development. Founded in 2011 and headquartered in Copenhagen, Denmark, it plays a role in the global effort to improve patient outcomes in oncology and fibrosis through targeted small molecule approaches.